# Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board, Advances Phase 3 Study to Support HyBryte(TM) Development for CTCL

* The expansion of Soligenix’s European Medical Advisory Board underscores the company’s commitment to delivering innovative treatment options to European patients.
* HyBryte (synthetic hypericin) is a first-in-class, photodynamic therapy using synthetic hypericin as a photosensitizer.
* The company’s efforts could establish HyBryte as a new standard of care for patients who currently have limited options.

 Cutaneous T-cell lymphoma (“CTCL”) is a rare but serious form of non-Hodgkin lymphoma that primarily affects the skin. Globally, millions suffer from CTCL, and in Europe, the annual incidence is estimated at 2.9 to 3.9 cases per million people (https://ibn.fm/ANk8X). Despite its rarity, CTCL presents a substantial unmet medical need, particularly in early-stage patients who often have limited treatment options. Addressing this gap, Soligenix (NASDAQ: SNGX) recently announced the expansion of its European Medical Advisory Board (“MAB”) (https://ibn.fm/6354Y) to provide additional clinical and strategic guidance as the company advances its confirmatory phase 3 study (referred to as FLASH2) evaluating the safety and efficacy of its proprietary CTCL treatment: HyBryte(TM).

 The expansion of Soligenix’s European MAB underscores the company’s commitment to delivering innovative treatment options to European patients. The announcement also notes a strategic step to ensure the successful execution of FLASH2 and to navigate the complex regulatory and clinical…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/soligenix-inc-nasdaq-sngx-expands-european-medical-advisory-board-advances-phase-3-study-to-support-hybrytetm-development-for-ctcl/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/soligenix-expands-european-advisory-board-for-ctcl-treatment/2e5b66fe88c16c6d2e50fb23a13dadcd) 


Pickup - [https://burstable.news/news](https://burstable.news/news/202510/248193-soligenix-expands-european-medical-advisory-board-to-advance-hybrytetm-development-for-cutaneous-t-cell-lymphoma)

Pickup - [https://estallarnoticias.com/](https://estallarnoticias.com//202510/248200-soligenix-amplia-su-consejo-asesor-medico-europeo-para-avanzar-en-el-tratamiento-de-linfoma-cutaneo-de-celulas-t)

Pickup - [https://platzennachrichten.de/nachrichten](https://platzennachrichten.de/nachrichten/202510/248352-soligenix-erweitert-europaisches-medizinisches-beratungsgremium-fur-ctcl-therapie-hybryte)

Pickup - [https://actueclair.com](https://actueclair.com/202510/248328-soligenix-elargit-son-conseil-consultatif-medical-europeen-et-progresse-dans-l-etude-de-phase-3-pour-hybrytetm-contre-le-lymphome-t-cutane)
 

 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/2510/9/apexxm9H.webp)